{
    "Disease activity (follow up: 4 months; assessed with: ACR 20)": {
      "No of studies": ["5"],
      "Study design": "randomised trials",
      "Risk of bias": "not serious",
      "Inconsistency": "not serious",
      "Indirectness": "not serious",
      "Imprecision": ["very serious", "a"],
      "Other considerations": "none",
      "No of patients": {
        "MTX monotherapy": "88/180 (48.9%)",
        "LEF": "95/182 (52.2%)"
      },
      "Effect": {
        "Relative (95% CI)": "RR 0.94 (0.76 to 1.15)",
        "Absolute (95% CI)": "31 fewer per 1,000 (from 125 fewer to 78 more)"
      },
      "Certainty": "LOW",
      "Importance": "CRITICAL"
    },
    "Disease activity (follow up: 4 months; assessed with: DAS28-ESR (Lower values â€“ > benefit) (MCID -1.17)": {
      "No of studies": ["6"],
      "Study design": "randomised trials",
      "Risk of bias": ["serious", "b"],
      "Inconsistency": "not serious",
      "Indirectness": "not serious",
      "Imprecision": ["very serious", "c"],
      "Other considerations": "none",
      "No of patients": {
        "MTX monotherapy": "21",
        "LEF": "19"
      },
      "Effect": {
        "Relative (95% CI)": "-",
        "Absolute (95% CI)": "MD 0.67 lower (1.5 lower to 0.16 higher)"
      },
      "Certainty": "VERY LOW",
      "Importance": "CRITICAL"
    }
  }